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Background: In Alzheimer’s disease synapse loss precedes neuronal loss and correlates best with impaired memory
formation. However, the mechanisms underlying synaptic degeneration in Alzheimer’s disease are not well known.
Further, it is unclear why synapses in AD cerebellum are protected from degeneration. Our recent work on the
cyclin-dependent kinase 5 activator p25 suggested that expression of the multifunctional presynaptic molecule
cysteine string protein alpha (CSPalpha) may be affected in Alzheimer’s disease.
Results: Using western blots and immunohistochemistry, we found that CSPalpha expression is reduced in
hippocampus and superior temporal gyrus in Alzheimer’s disease. Reduced CSPalpha expression occurred
before synaptophysin levels drop, suggesting that it contributes to the initial stages of synaptic degeneration.
Surprisingly, we also found that CSPalpha expression is upregulated in cerebellum in Alzheimer’s disease. This
CSPalpha upregulation reached the same level as in young, healthy cerebellum. We tested the idea whether
CSPalpha upregulation might be neuroprotective, using htau mice, a model of tauopathy that expresses the
entire wild-type human tau gene in the absence of mouse tau. In htau mice CSPalpha expression was found to
be elevated at times when neuronal loss did not occur.
Conclusion: Our findings provide evidence that the presynaptic vesicle protein CSPalpha is a key player in
synaptic degeneration and protection in Alzheimer’s disease. In the forebrain CSPalpha expression is reduced
early in the disease and this may contribute to the initial stages of synaptic degeneration. In the cerebellum
CSPalpha expression is upregulated to young, healthy levels and this may protect cerebellar synapses and
neurons to survive. Accordingly, CSPalpha upregulation also occurs in a mouse model of tauopathy only at time
when neuronal loss does not take place.
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Alzheimer’s disease is a devastating neurodegenerative con-
dition and the most prominent cause of dementia. The
neuropathological features of Alzheimer’s disease are sub-
stantial neuronal death in the forebrain, but almost no neu-
rodegeneration in the cerebellum [1,2]. In the forebrain
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unless otherwise stated.tangles are characteristic of Alzheimer’s disease. Further, syn-
aptic loss precedes neuronal loss and the former correlates
best with early deficits in memory formation [3,4]. Our re-
cent research provided a novel window into the mechanisms
underlying synaptic degeneration in Alzheimer’s disease [5].
We found that the truncated cyclin-dependent kinase 5 acti-
vator p25 is reduced in Alzheimer’s disease [6]. Normally,
p25 generation is linked to the synthesis of particular synap-
tic proteins, synaptogenesis and memory formation [6].
Thus, impaired p25 generation may cause early synaptic
dysfunction in Alzheimer’s disease. Furthermore, we dem-
onstrated that p25 generation regulates expression of theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Specificity of the anti-CSPalpha antibody used in
this study. The anti-CSPalpha antibody did not react with any
protein in forebrain and cerebellum from CSPalpha knockout (KO)
mice. In wild-type mice (WT) the antibody recognized a smear of
bands at an approximate molecular weight of 35 kiloDalton, indicating
complex postranslational modification of CSPalpha.
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alpha [6]. CSPalpha is a synaptic vesicle protein that be-
longs to a conserved gene family [7,8] that includes CSPalpha,
CSPbeta and CSPgamma of which only CSPalpha is
expressed in the brain [9,10]. CSPalpha function is essen-
tial for synaptic survival as indicated in mouse knockout
studies [10]. Furthermore, loss-of-function CSPalpha mu-
tations are responsible for autosomal dominant Kufs
disease, an adult-onset neurodegenerative disorder with
associated dementia [11,12]. CSPalpha is proposed to
serve various functions at the presynapse, including: 1)
Formation of a trimeric complex with SGT and Hsc 70,
resulting in a CSP/SGT/Hsc70 chaperone complex that is
localised at synaptic vesicles [13] and interacts with
SNARE proteins leading to calcium-triggered synaptic
vesicle exocytosis [14,15]. 2) Modulation of presynaptic
calcium levels by regulating the activity of presynaptic
calcium channels [8,16]. 3) Regulation of endocytosis
by facilitating dynamin 1 polymerization [17]. 4) Regu-
lation of the density of calcium-dependent K+ (BK)
channel at the presynaptic terminal, controlling the ex-
citability there [18,19].
Our finding that CSPalpha is a p25-regulated protein
[6] suggested that CSPalpha expression may be impaired
in Alzheimer’s disease. Here we tested this hypothesis by
examination of post-mortem human tissues. As expected,
we found that CSPalpha expression is reduced in forebrain
of early and late Alzheimer’s disease. Interestingly, CSPalpha
expression was reduced before synaptophysin levels
drop, suggesting that it contributes to the initial stages of
synaptic degeneration. Surprisingly, we discovered an up-
regulation of CSPalpha expression in Alzheimer’s disease
cerebellum, a brain area that is protected from synaptic
degeneration. Further post-mortem investigations and work
with a mouse model of tauopathy established a novel correl-
ation between CSPalpha upregulation and neuroprotection.
Results
Specificity of anti-CSPalpha antibody
To study CSPalpha protein expression we performed
western blots and immunohistochemistry with an anti-
CSPalpha antibody, which does not react with other pro-
tein in CSPalpha knockout mice [10] (Figure 1).
CSPalpha expression is reduced in post-mortem Alzheimer’s
disease hippocampus
The hippocampus is one of the earliest and one of the
most severely affected brain regions in Alzheimer’s disease
[20]. We studied whether CSPalpha protein expression is
affected in this brain region, comparing post-mortem
samples from severe Alzheimer’s disease patients (Braak
stages 5 and 6) and age-matched control subjects by west-
ern blot analysis. CSPalpha expression was normalized to
either the neuronal marker NSE or the synaptic markersynaptophysin (Figure 2A, C). In both cases CSPalpha
levels were significantly decreased in the hippocampus of
severe Alzheimer’s disease patients (referring to NSE ex-
pression: F(2,21) = 21.3; p < 0.01; referring to synaptophysin
expression: F(2,19) = 14.6, p < 0.05). This result suggests
that in severe Alzheimer’s disease CSPalpha expression is
not simply reduced as a result of neuronal or synaptic loss,
and that reduced CSPalpha expression may precede synap-
tic loss during the progression of Alzheimer’s disease.
Interestingly, we did not find that synaptopysin levels
are reduced in Alzheimer’s disease when normalized to
NSE expression (Additional file 1: Figure S1). In contrast
synaptophysin levels are reduced when absolute expression
levels are considered (e.g., [21-23]). Therefore, neuronal
loss in Alzheimer’s disease appears to mainly contribute to
reduced expression of synaptophysin, which can be cor-
rected for when expression is normalized to NSE.
We also analysed CSPalpha expression in mild Alzheimer’s
disease (Braak stages 1 and 2) (Figure 2B, D). Analysis of
western blot results revealed a significant decrease in
CSPalpha levels in the mild Alzheimer’s disease hippo-
campus when normalized with synaptophysin (F(2,20 =
4.26; P < 0.05), but showed no difference when normalized
with NSE (F(2,21 = 0.366, p = 0.427). These results indicate
that decreases in CSPalpha expression in the hippocam-
pus is an early event in Alzheimer’s disease.
Figure 2 CSPalpha protein expression is reduced in Alzheimer’s disease hippocampus. (A) CSPalpha expression in post-mortem hippocampus
from patients with severe Alzheimer’s disease (Braak stages 5 and 6; n = 12; average age at death = 75.2 ± 2.0 years) and control subjects (n = 12; average
age at death = 76.5 ± 2.9 years). CSPalpha expression was normalized against the neuron-specific house keeping marker protein NSE. (B) CSPalpha
expression in post-mortem hippocampus from patients with mild Alzheimer’s disease (Braak stages 1 and 2; n = 12; average age at death = 80.3 ± 3.2 years)
and control subjects (n = 12). CSPalpha expression was normalized against NSE. (C) The same samples as in panel (A) were used but CSPalpha expression
was normalized against the synaptic marker protein synaptophysin (severe Alzheimer’s disease, n = 11; control, n = 11). (D) The same samples as in
panel (B) were used but CSPalpha expression was normalized against synaptophysin (mild Alzheimer’s disease, n = 12; control, n = 11). Panel
(E) shows the representative western blots for 7 controls, 7 patients with severe AD and 7 patients with mild AD. Note that the anti-CSPalpha
antibody recognizes two bands at an approximate molecular weight range of 35 kiloDalton, which are likely to represent distinct post-translational
modifications of CSPalpha. Means ± s.e.m. are shown. *, p < 0.05; **, p < 0.01.
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superior temporal gyrus
We next studied CSPalpha expression in the superior
temporal gyrus (STG), which is affected later and less se-
verely than the hippocampus in Alzheimer’s disease. In a
western blot analysis we compared CSPalpha expression
in severe Alzheimer’s disease and control STG. The level
of CSPalpha expression was again normalised to NSE or
synaptophysin (Figure 3). In both cases, there was a
significant reduction in CSPalpha expression (referring
to NSE expression: F(2,22) = 14.8; p < 0.01; referring to
synaptophysin expression: F(2,22) = 7.48, p < 0.001), simi-
lar to that found in the hippocampus (Figure 2A, C).
These results show that changes in CSP levels are not
limited to the hippocampus in Alzheimer’s disease
brain, but are also found in other degenerating fore-
brain regions.CSPalpha expression is increased in Alzheimer’s disease
cerebellum
The cerebellum is the least affected brain structure in
Alzheimer’s disease [1,2]. There is no synapse and neur-
onal loss in this brain region in this disease. We investi-
gated the levels of CSPalpha expression in cerebellum
from severe Alzheimer’s disease and controls, using west-
ern blot analysis. As in the case of hippocampus,
CSPalpha amounts were normalized against NSE and
synaptophysin (Figure 4A, C). In both cases CSPalpha
levels were significantly increased by about 50% (referring
to NSE expression: F(2,17) = 2.76; p < 0.05; referring to
synaptophysin expression: F(2,17) = 5.28, p < 0.01). We
also analysed CSPalpha expression in mild Alzheimer’s
diseaseand control cerebellum (Figure 4B, D). We found
that the level of CSPalpha expression was significantly in-
creased in mild Alzheimer’s disease cerebellum when
Figure 3 CSPalpha protein expression is reduced in Alzheimer’s disease superior temporal gyrus. (A) CSPalpha expression in post-mortem
STG from patients with severe Alzheimer’s disease (n = 13; average age at death = 73.2 ± 3.4 years) and control subjects (n = 12; average age at
death = 76.9 ± 2.1 years). CSPalpha expression was normalized against NSE. (B) The same samples as in panel (A) were used but CSPalpha expression
was normalized against synaptophysin (severe Alzheimer’s disease, n = 13; control, n = 12). Panel (C) shows the representative western blots for
5 controls and 5 patients with severe AD. Means ± s.e.m. are shown. **, p < 0.01; ***, p < 0.001.
Figure 4 CSPalpha expression is increased in Alzheimer’s disease cerebellum. (A) CSPalpha expression in post-mortem cerebellum from patients
with severe Alzheimer’s disease (n = 10; average age at death = 74.7 ± 4.0 years) and control subjects (n = 10; average age at death = 76.3 ± 4.2 years).
CSPalpha expression was normalized against NSE. (B) CSPalpha expression in post-mortem cerebellum from patients with mild Alzheimer’s
disease (n = 10; average age at death = 81.3 ± 4.1 years) and control subjects (n = 10). CSPalpha expression was normalized against NSE. (C) The
same samples as in panel (A) were used but CSPalpha expression was normalized against synaptophysin. (D) The same samples as in panel (B) were
used but CSPalpha expression was normalized against synaptophysin. Panel (E) shows the representative western blots for 5 controls, 5 patients with
mild AD and 5 patients with severe AD. Means ± s.e.m. are shown. *, p < 0.05; **, p < 0.01.
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to NSE expression: F(2,17) = 7.25; p < 0.05; referring to
synaptophysin expression: F(2,17) = 4.18, p < 0.05). There-
fore, we have observed reduced CSPalpha amounts in de-
generating regions of early and severe Alzheimer’s disease
brain, and increased levels of CSPalpha in areas of
Alzheimer’s disease brain that are relatively spared from
degeneration. These findings suggest that there may be a
mechanistic link between CSPalpha expression levels and
neuroprotection in Alzheimer’s disease.Figure 5 Increased CSPalpha immunostaining in Alzheimer’s disease
severe Alzheimer’s disease (B, D) and a control subject (A, C) were probed
CSPalpha expression in the cerebellar cortex of the Alzheimer’s disease pat
cortex with the Purkinje cell layer and granule cells are visible in the lower
Alzheimer’s disease as compared to an age-matched control case. In C and
and neuropil labeling in Alzheimer’s disease as compared to an age-matched con
with omission of the primary antibody) and confirm the specificity of labeling
is also shown. Original magnification: 400×. Scale bars represent 20 μm.Immunohistochemical analysis confirms CSPalpha
downregulation in forebrain and upregulation in
cerebellum in Alzheimer’s disease
To confirm the changes in CSPalpha protein amounts
determined by western blotting, we carried out a qualita-
tive immunohistochemical analysis with post-mortem cere-
bellum, hippocampus and STG from a severe Alzheimer’s
disease patients and a control subject (Figure 5; Additional
file 2: Figure S4). A neuropathologist blinded to the
disease state of the tissue performed a qualitativecerebellum. Fixed cerebellar cortex sections from a patient with
with anti-CSPalpha antibodies for analysis of CSPalpha expression.
ient appeared higher than in the control subject. In A and B cerebellar
right corner. There is increased immunoreactivity in the neuropil in
D the granule cells of the cerebellum show increased cytoplasmic
trol. Negative control images are shown in E and F (immunohistochemistry
in Figure 5 and Additional file 1: Figure S1. Haematoxylin counterstaining
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confirmed an increase in CSPalpha levels in cerebellar
regions (Figure 5) and a decrease in hippocampus and
STG in severe Alzheimer’s disease compared to control
(Additional file 2: Figure S4). To validate the synaptic
specificity of the anti-CSPalpha antibodies, the immu-
nohistochemistry was compared with synaptophysin ex-
pression patterns (Additional file 3: Figure S2). Staining
of cerebellar dentate nucleus from a control subject
showed similar results with both antibodies, confirming
that the CSPalpha immunostaining was typical for syn-
aptic staining.
CSPalpha expression is not changed in frontotemporal
lobar degeneration (FTLD) cerebellum
Frontotemporal lobar degeneration (FTLD) is a promin-
ent form of dementia that is characterized by neurode-
generation of the frontotemporal region [24]. In addition
to frontal lobe degeneration, the cerebellum is also re-
ported to be affected in FTLD cases [25]. This disparity
provided an opportunity to test the specificity of our ob-
servation that CSPalpha is upregulated in Alzheimer’s
disease cerebellum. We performed a western blot ana-
lysis to study whether altered CSPalpha expression is
linked to cerebellar neuropathology in FTLD (Figure 6).
CSPalpha expression levels did not differ between FTLDFigure 6 CSPalpha expression in cerebellum is not changed in
FTLD. CSPalpha expression in post-mortem cerebellum from patients
with FTLD (n = 5; average age at death = 73.0 ± 3.0 years) and control
subjects (n = 5; average age at death = 70.2 ± 7.2 years).CSPalpha
expression was normalized against NSE (A). Panel (B) shows the
representative western blots for 5 controls and 5 patients with
FTLD. Means ± s.e.m. are shown.and control cerebellum (t = − 0.373, p = 0.72). Hence, in-
creased CSPalpha expression in the cerebellum is not a
common feature of neurodegenerative disease, but ap-
pears to be specific for Alzheimer’s disease.
Normal ageing reduces CSPalpha expression in human
cerebellum
The difference in CSPalpha expression in the hippocampus
and cerebellum of Alzheimer’s disease brain suggests that
CSPalpha expression may be differentially regulated under
physiological and/or pathological conditions. Therefore, we
studied whether normal ageing also regulates CSPalpha ex-
pression in cerebellum. Using western blots, we analysed
CSPalpha protein expression in cerebellum from healthy
subjects belonging to two age groups, 15–30 years (21.3 ±
1.6 years) and 90–105 years (96.1 ± 1.4 years) (Figure 7).
CSPalpha expression was reduced by approximately 50% in
the aged cerebellum when expression was normalized to
NSE expression (t = 2.443; p < 0.05). Similarly, when nor-
malized to synaptophysin levels the average CSPalpha ex-
pression in the aged cerebellum appeared lower than in
young cerebellum, although this did not reach significance
(t = 1.351; p = 0.23), most likely due to a large variability of
CSPalpha amounts in young cerebellum. Taken together,
our results suggest that CSPalpha amounts are subject to
age-dependent decreases in healthy cerebellum. Interest-
ingly, the CSPalpha expression level in Alzheimer’s disease
cerebellum is similar to the expression level found in
young healthy cerebellum.
Overexpression of human tau leads to an age-dependent
decline in hippocampal-cortical CSPalpha levels
Together with amyloid plaques, neurofibrillary tangles
containing hyperphosphorylated tau aggregates are a
pathological hallmark of Alzheimer’s disease. We investi-
gated the levels of CSPalpha in a mouse model of tauo-
pathy that which expresses the entire wild-type human
tau gene in the absence of mouse tau [26]. These mu-
tants progressively develop hyperphosphorylated tau and
form neurofibrillary tangles predominantly in the cortex
and hippocampus. This model also has deficits in basal
synaptic transmission, long-term potentiation and mem-
ory, and a widespread neuronal loss in old age [27,28].
The tau pathology is visible with biochemical analysis
from 3 weeks of age, but neuronal loss is only appar-
ent from 17 months of age onwards. We studied CSPalpha
expression in the hippocampus/overlying cortex
(Figure 8A, Additional file 4: Figure S3), frontal cortex
(Figure 8B) and cerebellum (Figure 8C) of htau mu-
tants and wild-type mice at 3–4 months of age. We
found a significant upregulation of CSPalpha expression
in hippocampus (Figure 8A, t = 6.539, p < 0.001), frontal
cortex (Figure 8B, t = 8.005, p < 0.001) and cerebellum
(Figure 8C, t = 5.200, p < 0.001) in 3–4 month-old htau
Figure 7 Normal ageing reduces CSPalpha expression in healthy human cerebellum. (A) CSPalpha expression in post-mortem cerebellum
from healthy young (n = 6; average age at death = 21.3 ± 1.6 years) and aged (n = 7; average age at death = 96.1 ± 1.4 years) subjects. CSPalpha
expression was normalized against NSE. (B) The same samples as in panel (A) were used but CSPalpha expression was normalized against synaptophysin.
Panel (C) shows the representative western blot for 6 young subjects and 7 aged subjects. Means ± s.e.m. are shown. *, p < 0.05.
Figure 8 Mice expressing human tau have an age-dependent CSPalpha upregulation that correlates with neuroprotection. (A) CSPalpha
expression in hippocampus of young (3–4 months) wild type (n = 6) and htau mice (n = 6). (B) CSPalpha expression in cortex of young (3–4 months)
wild type (n = 6) and htau mice (n = 6). (C) CSPalpha expression in cerebellum of the same mouse sample as in panel (A) and (B). (D) CSP alpha
expression in old (24 months) wild type (n = 4) and htau mice (n = 7). CSPalpha expression was normalized against NSE in all panels. Panel (E) shows
the representative western blots. Means ± s.e.m are shown. ***, p < 0.001.
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loss in htau mice, and therefore this findings is in agree-
ment with the idea that increased CSPalpha expression
may be a neuroprotective mechanism. We also investigated
CSPalpha expression at 24 months of age in hippocampal/
overlying cortex lysates prepared from htau and wild type
mice (Figure 8D). At this age point no differences in the
levels of CSPalpha in the hippocampus from wild type and
htau mice was apparent (Figure 8D, t = −0.220, p =0.83).
Thus, at a time point when neuronal loss is observed,
CSPalpha expression is no longer elevated.
Discussion
The main findings of our study are that 1) expression of
CSPalpha is reduced in degenerating forebrain in mild
and severe Alzheimer’s disease. This downregulation oc-
curs before synaptophysin levels drop. 2) CSPalpha expres-
sion is upregulated in Alzheimer’s disease cerebellum, a
brain region protected from synaptic and neuronal loss in
Alzheimer’s disease. This upregulation is at a level that oc-
curs in young healthy cerebellum. 3) CSPalpha expression
is not upregulated in FTLD cerebellum where neuropath-
ology occurs. 4) In a mouse model of tauopathy CSPalpha
upregulation inversely correlates with neurodegeneration.
Taken together, these findings provide evidence that CSPalpha
is a critical player of synaptic degeneration and synaptic
survival in Alzheimer’s disease.
CSPalpha is a p25-regulated protein, and we have pre-
viously shown that p25 expression is downregulated in
Alzheimer’s disease forebrain [6]. In addition, loss-of-
function CSPalpha mutations cause adult-onset Kufs dis-
ease that is associated with dementia [11,12]. We therefore
speculated that CSPalpha expression could be altered in
Alzheimer’s disease. Here we confirm this idea. We found
that CSPalpha expression is reduced in hippocampus and
STG in severe Alzheimer’s disease. In western blots we de-
tected CSPalpha as two bands due to posttranslational
modifications. The posttranslational modifications and the
levels of CSPalpha appear variable within a given group.
However, when normalized to NSE or synaptophysin and
when outliers were excluded (see, Material and methods)
significant differences in expression between groups were
identified. Our finding that CSPalpha expression is re-
duced in AD hippocampus and STG is consistent with an-
other study, which was published after we started our
project, showing that in Brodmann area 9 of severe
Alzheimer’s disease CSPalpha expression is reduced by
about 40% [29]. Furthermore, we also detected a down-
regulation of CSPalpha expression in hippocampus in
mild Alzheimer’s disease when CSPalpha amounts were
normalized to the synaptic marker synaptophysin. Trad-
itionally, synaptophysin is used as a neuropathological
marker of synaptic degeneration in Alzheimer’s disease
[3]. However, our finding that CSPalpha levels are reducedwithout noticeable changes in synaptophysin expres-
sion, when relative neuronal expression rather than abso-
lute protein expression is analyzed. When considering the
importance of CSPalpha for synaptic function [10], our
findings suggest that reduced CSPalpha expression is
likely to be involved in the initial stages of synaptic de-
generation. Further, for investigating synaptic degener-
ation in Alzheimer’s disease analysis CSPalpha expression
appears more suitable than assessing synaptophysin
expression.
CSPalpha, along with its interacting partners Hsc-70
and SGT, is involved in exocytotic mechanisms in pre-
synaptic terminals that are mediated by its interactions
with SNARE complexes [9]. Downregulation of CSPalpha
may therefore lead to reductions in the number of syn-
aptic vesicles binding at presynaptic membranes, thereby
affecting synaptic activity. Further, CSPalpha is also import-
ant for endocytosis of synaptic vesicles. CSPalpha interacts
with dynamin to facilitate the of dynamin polymerization
which is important for endocytotic vesicle fission [17,29].
This is important for normal synaptic function since the
number of synaptic vesicles readily available for exocytosis
is reduced when there are defects in endocytotic fission
[30]. This suggests that defects observed in exocytotic
mechanisms in CSPalpha knockout mice could be ex-
plained by deficits in CSPalpha-dependent endocytotic
mechanisms. Hence, CSPalpha downregulation could lead
to loss of function at different stages of synaptic vesicular
recycling to contribute to synaptic loss. Additionally, re-
duced CSPalpha expression is expected to increase BK
channel density at synapses, which reduces excitability at
presynaptic terminals [18,19]. BK channel activation has
been reported to decrease basal synaptic transmission in
hippocampal CA1 region of a mouse model of Alzheimer’s
disease [31]. Loss of synaptic activity is thought to be lethal
for synapses, therefore, the downregulation in CSPalpha ex-
pression we observe in Alzheimer’s disease hippocampus
could be closely associated with synaptic degeneration
and the resulting impaired memory formation in early
Alzheimer’s disease.
The second major finding from our study is the identi-
fication of CSPalpha upregulation in Alzheimer’s disease
cerebellum. The cerebellum is relatively protected from
neurodegeneration in Alzheimer’s disease. For example,
there is no synaptic and neuronal loss in this area, al-
though there are some diffuse amyloid plaques [1]. The
molecular mechanisms that impart neuroprotection to
the cerebellum in Alzheimer’s disease are not known.
Our results suggest that CSPalpha may be a factor con-
tributing to this neuroprotection. We observed an up-
regulation of CSPalpha in cerebellum both in mild and
severe Alzheimer’s disease. Importantly, we found that
the level of upregulation in this region is comparable to
the amounts of CSPalpha expression detected in young,
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decrease in CSPalpha expression in normal cerebellum.
Additional experimental support for the suggestion
that CSPalpha upregulation could be neuroprotective
in Alzheimer’s disease comes from our finding that
CSPalpha expression is not altered in cerebellum from
patients with FTLD, although there is neuropathology
in the cerebellum in this disease [25,32,33]. Additional
support for our hypothesis comes from analysis of htau
mutant mice, where we found that CSPalpha upregula-
tion occurs only at times when no neuronal loss is ob-
served. Taken together, the evidence we present here
suggests that CSPalpha upregulation in Alzheimer’s
disease cerebellum might be neuroprotective, although
in future functional studies in model systems are needed
to support this idea.
How could CSPalpha upregulation protect synapses and
consequently neurons in Alzheimer’s disease cerebellum?
In Alzheimer’s disease forebrain, amyloid-induced aberra-
tions in synaptic activity are one of the causes of synaptic
toxicity [34]. In particular, dysfunctional synaptic machin-
ery could be an after-effect of impaired synaptic vesicle
trafficking. Aβ oligomers impair synaptic vesicle recycling
by hindering endocytosis as well as the formation of
fusion-competent vesicles [35]. Furthermore, transgenic
mouse studies have suggested that presynaptic degener-
ation is pivotal in Alzheimer’s disease [36]. Considering
the role of CSPalpha in endocytosis and vesicle recycling,
an up regulation of CSPalpha in Alzheimer’s disease cere-
bellum could be a compensatory mechanism that prevents
impairments in synaptic vesicle recycling that are induced
by factors causing Alzheimer’s disease. This might result
in protection of synapses and neurons from degeneration.
Functional studies with CSPalpha knockout and upregula-
tion models will provide further insights into the mechan-
istic basis of our observations.
Conclusion
Synapse loss in forebrain, but not cerebellum, is a key
hallmark of in Alzheimer’s disease. However, the mecha-
nisms causing brain region-dependent synapse loss and
protection are unknown. Here we provide evidence that
the presynaptic vesicle protein CSPalpha is a critical
player in Alzheimer’s disease. In the forebrain CSPalpha
expression reduces in the initial stages of synaptic de-
generation before synaptophysin levels drop. In cerebel-
lum CSPalpha expression is upregulated both in mild and
severe Alzheimer’s disease. This upregulation of CSPalpha
is to a level that occurs in young health cerebellum. In a
mouse model of tauopathy we confirmed a lack of
neuronal loss when CSPalpha expression is elevated.
Taken together, these findings point to critical role for
CSPalpha in synaptic degeneration and protection in
Alzheimer’s disease.Material and methods
Post-mortem human brain samples
Brain tissues in 10% (v/v) formalin-fixed, paraffin-embedded
tissue blocks and as frozen tissues were available from the
Medical Research Council (MRC) London Neurodegenera-
tive Diseases Brain Bank (Institute of Psychiatry, King’s
College London, UK). All tissue collection and processing
was carried out under the regulations and licensing of the
Human Tissue Authority and in accordance with the Hu-
man Tissue Act, 2004. Frozen samples were received in
two sets for western blot analysis. The first set contained
hippocampal tissue from control subjects, mild Alzheimer’s
disease (Braak stages 1–2) and severe Alzheimer’s disease
(Braak stages 5–6) [n = 7 for each group], as well as su-
perior temporal gyrus (STG) samples from controls and
severe Alzheimer’s disease [n = 7 and n = 9, respect-
ively]. The second set comprised hippocampus, STG
and cerebellum samples from control, mild and severe
Alzheimer’s disease patients (n = 5 for each group). To
increase the sample size of cerebellum, a new cohort
(n = 5 per group) was later added to the analysis. Cerebel-
lum samples (n = 5) were obtained from frontotemporal
lobar degeneration (FTLD) patients. Cerebellum tissues
were also obtained from healthy subjects less than 30 years
old (n = 6) and older than 90 years (n = 7). Additional file 5:
Table S1 summarizes the details.
Lysate preparation from human brain samples
Frozen brain samples were lysed at 4°C in RIPA lysis
buffer (Santa Cruz Biotechnology, Inc., USA) consisting
of 0.1% SDS, 1% Nonidet P-40, 0.5% sodium deoxycholate
and 0.004% sodium azide in TBS (pH 7.5). Protease inhibi-
tors cocktail, sodium orthovanadate and α-toluenesulphonyl
fluoride in DMSO (all Santa Cruz Biotechnology, Inc., USA)
were added to the buffer, diluted to 0.01%. The SDS concen-
tration was increased to 0.25%. Approximately 100 mg of
brain tissue was lysed in 300 μl buffer. Samples were ho-
mogenized using a dounce homogenizer (12 up and down
strokes, 700 rotations per minute) at 4°C, and centrifuged at
3,000 rpm for 10 minutes at 4°C. Supernatants were immu-
noblotted and the bands from protein of interest were nor-
malized with housekeeping proteins.
Mouse brain samples
Frontal cortex, cerebellum and hippocampus/overlying cor-
tex was isolated from 3–4 month old human tau (htau)
mice in the C57BL/6 J background (Jackson Laboratories,
Bar Harbor, Maine USA; Stock number: 005 491). Mice
were genotyped by PCR to confirm the presence of the hu-
man MAPT transgene and the mouse Mapt null back-
ground using primers for the MAPT gene (forward 5′-AC
TTTGAACCAGGATGGCTGAGCCC-3′, reverse 5′-CTG
TGCATGGCTGTCCCTACCTT-3′), and the mouse Mapt
gene (forward 5′-CTCAGCATCCCACCTGTAAC-3′,
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scribed in [20]. The primers for the disrupted Mapt
gene were: forward 5′-AAGTTCATCTGCACCACC
G-3′, reverse 5′-TCCTTGAAGAAGATGGTG CG-3′.
Mice were housed on 12 h light:12 h dark cycles with food
and water available ad libitum. Mice were killed by cervical
dislocation and brain regions snap frozen on dry ice. All ani-
mal procedures were conducted in accordance with the UK
Home Office, Animals Scientific Procedures Act 1986.
Lysate preparation from mouse brain samples
Frozen tissue was homogenised at 100 mg/ml in 2× sample
buffer (0.5 M Tris–HCl, pH 6.8, 4.4% SDS, 20% glycerol,
2% 2-mercaptoethanol, 0.01% bromophenol blue, and
complete mini-protease inhibitor cocktail (Roche Products
Ltd., UK). Following brief sonication, homogenates were
centrifuged at 25,000 g for 20 minutes at 4°C, and the
supernatant was collected.
Western blot analysis
The same protein amounts were separated on criterion
TGX precast gels (4-15%) gels (BioRad) and the protein
was transferred onto a methanol activated PVDF mem-
brane (BioRad), using standard protocols. Non-specific
binding was blocked by 5% non-fat dried milk in TBST
for 1 hour at room temperature. Subsequently, mem-
branes were incubated overnight at 4°C in primary anti-
body solution prepared in blocking buffer. After three
ten minute washes in TBST at room temperature, mem-
branes were incubated for two hours at room temperature
with horse-radish peroxidase conjugated secondary anti-
bodies in blocking buffer. After three ten minute washes
with TBST, the membrane was incubated for 3 minutes in
ECL reagent (Thermo Scientific) and then exposed to an
X-ray film (Amersham) in the linear range. To probe the
membranes with other primary antibodies, membranes
were treated with a stripping buffer (Santa Cruz Biotech-
nology) for one hour at room temperature, followed by
three washes with TBST of 10 minutes each and subse-
quent labelling as described above. Primary antibodies
against CSPalpha (1:50,000, AB1576 Merck Millipore),
synaptophysin (1:1000, 4329 Cell Signalling Technology)
and neuron specific enolase (NSE) (1:60,000, AB 951 Merck
Millipore) were used. Signals were analyzed using ImageJ
software (NIH). With the antibodies against CSPalpha
sometimes two bands were detected in human post-
mortem brain. These bands are not CSPbeta and
CSPgamma since these proteins are not expressed in
brain [10]. For standardization CSPalpha was normal-
ized against NSE or synaptophysin.
Immunohistochemistry
Sections of human brain of 7 μm thickness were cut
from paraffin-embedded tissue blocks. Sections weredeparaffinised in xylene and rehydrated in ethanol. En-
dogenous peroxidase activity was blocked by incubation
of sections with 2.5% H2O2 in methanol. To enhance
antigen retrieval sections were exposed to citrate buffer
(2.94 g/L, pH 6.0) for 16 minutes microwave treatment
(6 minutes high, two 5 minutes simmer). After blocking
in normal swine serum (DAKO Ltd), primary antibodies
against CSPalpha (1:500, AB1576 Merck Millipore), and
synaptophysin (1:100, SY38 DAKO Ltd) were applied
overnight at 4°C. Following rinsing and two five minutes
washes in TBS, sections were incubated with appropriate
biotinylated secondary antibodies (1:100, Swine anti-rabbit
immunoglobulin/biotinylated, E0353 DAKO Ltd), followed
by incubation with avidin:biotin enzyme complex (Vectas-
tain Elite ABC kit, Vector Laboratories, Peterborough,
UK). Following washing, sections were incubated for
10–15 min with 0.5 mg/ml 3,3′-diaminobenzidine
chromogen (Sigma-Aldrich Company Ltd, Dorset UK)
in Tris-buffered saline (pH 7.6) containing 0.05% H2O2.
Sections were counterstained with Harris’s haematoxylin.
Statistical analysis
Un-paired t tests were used for comparison of data from
samples tested in one western blot. – In some cases, the
sample size was so large so that data from more than
one western blot needed to be pooled. To allow pooling
of data by linear regression, the following equation was
used -
CSP
NormalizationMarker
NSE; Synaptophysinð Þ
0
B@
1
CA
i
¼ β0 þ β1  X1i þ β2  X2i þ εi
Where X1i is the categorical predictor coding for the
group difference (e.g. Control versus Severe), and X2i is
the categorical predictor coding for the different experi-
ments (“1stcohort” versus “2ndcohort”).
This regression model allowed us to pool the CSPalpha
score from two different set of samples by eliminating the
contribution made by the difference in experimental con-
ditions. This analysis was performed using SPSS (version
20), which provides the output as an ANOVA score. The
contribution and the significance of the factor of interest
(e.g. the disease pathology) to the overall significance is
subsequently determined by the score from this output.
The level of significance for the analysis was 0.05 and out-
liers were decided by using mean ± 4*SD as threshold. See
Additional file 6 in supplementary information for analysis
of post-mortem brain tissue.
Additional files
Additional file 1: Figure S1. Synaptophysin protein expression in
reference to NSE expression is unchanged in Alzheimer’s disease
Tiwari et al. Molecular Brain  (2015) 8:6 Page 11 of 12hippocampus. (A) Synaptophysin expression in post-mortem hippocampus
from patients with severe AD (n = 12) and control subjects (n = 12) was
normalized against the neuron specific house keeping marker protein NSE.
(B) Synaptophysin expression in post-mortem hippocampus from patients
with mild AD (n = 12) and control subjects (n = 12) was normalized against
NSE. Means ± s.e.m. are shown. *, p < 0.05; **, p < 0.01.
Additional file 2: Figure S4. Decreased CSPalpha immunostaining in
Alzheimer’s disease hippocampus and STG. Fixed hippocampal sections
from a patient with severe Alzheimer’s disease (D) and an age-matched
control subject (C) were probed with anti-CSPalpha antibodies for analysis
of CSPalpha expression.Sections from the hippocampus with the granule
cell layer show decreased immunoreactivity with a synaptic staining pattern
in Alzheimer’s disease as compared to the control case. A similar analysis
was carried out for expression in superior temporal gyrus (STG) from a
patient with severe Alzheimer’s disease (B) and an age-matched control
subject (A). In the STG there is decreased immunoreactivity in Alzheimer’s
disease as compared to control. Haematoxylin counterstain is included in
the analysis. Original magnification: ×400. Scale bars represent 20 μm.
Additional file 3: Figure S2. CSPalpha immunostaining in cerebellum
is typical for synaptic expression. Immunohistochemical sections of
cerebellar dentate nucleus region from a control patient were
immunostained with anti-CSPalpha antibodies (A) and with antibodies
against the synaptic marker synaptophysin (B). This comparison indicated
that the CSPalphaimmunostaining is synaptic as obtained for synaptophysin
immunostaining. Scale bars represent 200 μm.
Additional file 4: Figure S3. Synaptophysin levels relative to NSE
expression are unchanged in hTau mutant mouse hippocampus.
Synaptophysin expression in hippocampus of young (3–4 months) wild
type (n = 6) and hTau mice (n = 6) was normalized against NSE in all
panels. Means ± s.e.m are shown.
Additional file 5: Table S1. Details of post-mortem brain tissues for
western blots. PMD refers to post-mortem delay.
Additional file 6: Statistical analysis of the effect of age, gender and
post mortem delay on post-mortem brain tissues used in this study.
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